Monthly Archives: September 2017

What’s in a name? That which we call a rose by any other name would smell as sweet.William Shakespeare, Romeo and Juliet (Act 2, Scene 2, Page 2) Continue reading →

The United States has lead the way in developing organ-sharing algorithms with emphasis on reducing waiting-list mortality.1 Allocation based on the Model for End-stage Liver Disease score has been a revolutionary measure, not just for upholding the pr… Continue reading →

The National Institutes of Health (NIH) is the major funder of research in gastrointestinal (GI) diseases. The National Institute for Diabetes and Digestive and Kidney Diseases’ discretionary appropriation for fiscal 2016 is $1.818 billion of the ove… Continue reading →

Dietary management makes sense in patients with irritable bowel syndrome, because food is a major inducer of symptoms, and dietary manipulation empowers patients to influence the outcome of their disorder. It is not surprising, therefore, that the arri… Continue reading →

The first endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) was performed in 1991 for the diagnosis of mucinous cystadenoma of the pancreas.1 Since then, endoscopic ultrasound imaging has advanced with regard to the diagnosis of panc… Continue reading →

Intestinal fibrosis remains one of the largest clinical challenges in the field of inflammatory bowel diseases.1 More than one-half of the patients with Crohn’s disease develop clinically apparent fibrostenosis throughout their disease course, leadin… Continue reading →

Kamphorst AO, Wieland A, Tahseen Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science 2017;355:1423-1427. Continue reading →

In a large cohort of patients with chronic hepatitis C infection, sustained virologic response after direct-acting antiviral therapy lowered, but did not eliminate, the risk of hepatocellular carcinoma. Continue reading →

The development of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection was well-received by patients and physicians, as viral clearance is associated with improved liver-related and overall survivals.1,2 Despite this … Continue reading →

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease is a comprehensive review of the use of anti-tumor necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD). The book includes a preface and 35 chapters, which can … Continue reading →